Additional exploratory analysis measuring quality of life, anxiety and depression assessments was next analyzed to evaluate how CYP2D6/CYP2C19-C and CYP2D6/CYP2C19-I subgroups changed over the course of treatment. This evidence concerns the gene CYP2C19 and depressive disorder.